About: Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Sector: Healthcare
Industry: Biotechnology
Latest price: $9.15 (-3.68%)
DTIL NASDAQ Precision BioSciences Inc
Precision BioSciences Inc share price
Atividade de preço de DTIL
Último preço
$ 9,150
Variação (24h)
-0,35 USD (3,68%)
Volume
251.72K
Volume (média 4 sem.)
-
Abertura
$ 9,46
Variação do dia
$ 8,93 - $ 9,59
Fechamento anterior
$ 9,50
Último negócio
11 Nov, 9:18 pm GMT+0
Atrasado
11 Nov, 9:18 pm GMT+0
DTIL price performance
Atrasado
11 Nov, 9:18 pm GMT+0
DTIL details
quote.marketSignals